# Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

> **NCT04246723** · PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 85 (actual)

## Conditions studied

- Chronic Hepatitis c Genotype 1

## Interventions

- **DRUG:** Narlaprevir
- **DRUG:** Ritonavir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT04246723
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2020-04-08
- **Final completion:** 2020-08-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04246723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04246723, "Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04246723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*